Molecular Mechanism of Gleditsiae Spina for the Treatment of High-Grade Serous Ovarian Cancer Based on Network Pharmacology and Pharmacological Experiments

Figure 6

Molecular docking of compounds with core targets: (a) AKT1-genistein, (b) AKT1-luteolin, (c) CTNNB1-genistein, (d) CTNNB1-luteolin, (e) HPSE-genistein, (f) HPSE-luteolin, (g) PIK3CA-genistein, and (h) PIK3CA-luteolin.